Hims & Hers Health, Inc. (HIMS) Stock: Price, Forecast & Analyst Target
Hims & Hers Health, Inc. (HIMS) — MoonshotScore 31/100 (Weak band), calculated Nov 18, 2026. Price $16.02 (-6.04%), as of the Nov 19, 2026 trading session; market cap $3.76B.
Educational signal · not a buy or sell recommendation · How to read this
Hims & Hers Health, Inc. · HIMS · NYSE · Healthcare · Medical - Care Facilities
Research dated 2026-09-13: The company operates a telehealth platform connecting patients with licensed clinicians for prescriptions and over-the-counter wellness products. Profitability has vanished in the most recent quarters despite sustained revenue growth, and the question is whether this signals a structural problem with unit economics or a temporary squeeze that resolves as the platform scales.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Hims & Hers Health (HIMS)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a fragile balance sheet and a full valuation. The score also carries a risk penalty for a bankruptcy-risk score in the grey zone and losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Flat; Momentum: Slipping.
- EPS beat 0 of the last 4 reports
- Altman Z 1.18 · Piotroski F 2
- ROE -40.8% · ROA -4.0% · current ratio 0.92
Holding back: balance-sheet strain
Helping: business quality
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 32 | Weak | |
| 32 | Weak | |
| 32 | Weak | |
| 32 | Weak | |
| 31 | Weak | |
| 31 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $16.02 | |
| Change on the day | -6.04% | |
| 52-week range | $13.74–$40.99 | |
| Market capitalisation | $3.76B | — |
| Price / earnings (trailing) | 50.00 | |
| Shares traded on the day | 13.42M | |
| Beta (volatility vs the S&P 500) | 2.5 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Hims & Hers Health (HIMS): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Griffin-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Hims & Hers Health (HIMS), and what does it report?
Short answer · as of
The platform generates revenue from virtual consultations billed to insurance and patient copays alongside direct-to-consumer sales of medications and wellness products.
Research dated 2026-09-13.
The reporting combines these into aggregate revenue, making it difficult for investors to isolate high-margin consultations from lower-margin product sales.
The company carries substantial debt while operating at gross margins typical of commodity retail.
What do the latest results show for Hims & Hers Health (HIMS)?
Research dated 2026-09-13.
The most recent quarter showed operating losses widen even as revenue accelerated, meaning incremental sales generated less operating profit than the prior period. Selling and general expenses contracted as a percentage of revenue, but research and development expense rose, suggesting the company is investing in competitive differentiation while profitability deteriorates.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $599M | $16M | $0.06 (diluted) |
| Q4 FY2025 | $618M | $21M | $0.08 (diluted) |
| Q1 FY2026 | $608M | -$92M | -$0.40 (diluted) |
| Q2 FY2026 | $753M | -$86M | -$0.37 (diluted) |
What are the financial strengths and risks for Hims & Hers Health (HIMS)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
Gross margins remain robust, providing cushion for operating expenses, but the balance sheet shows liquidity metrics that fall short of prudent standards and leverage ratios that exceed comfortable thresholds, meaning the company has limited liquid assets to cover near-term obligations if revenue stalls.
The most pressing risk is that revenue growth masks deteriorating unit economics in customer acquisition or retention.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 1.18 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-40.8%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 2 of the last 4 reported quarters.
What should you watch next at Hims & Hers Health (HIMS)?
Short answer · as of
Current published price targets run low $24.00 · high $40.00 · consensus $31.00 · median $32.00 against a quoted price of $16.02 (as of Nov 19, 2026).
Research dated 2026-09-13.
Insiders have sold continuously over the most recent period with no offsetting purchases, which typically signals weak conviction about near-term recovery. Watch whether the next reported quarter returns to profitability or the loss persists, because sustained operating losses would suggest recent earnings swings are not seasonal noise.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Hims & Hers Health compare with its peers?
Short answer
Hims & Hers Health's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Most digital health platforms operate under the same margin and cash-consumption trade-off: either they push through to profitability by cutting customer acquisition spending, or they accelerate acquisition and defer profits. Hims is distinctive in its exposure to over-the-counter product sales, which are lower margin than prescription services but can build retail loyalty. That mix is unique among telehealth peers and represents the company's strategic differentiation.
| Company | Price | Market value | Score |
|---|---|---|---|
| $120.85 Nov 18, 2026 | $2.25B | 93 5-pillar Nov 18, 2026 | |
| $320.00 Nov 19, 2026 | $12.6B | 92 5-pillar Nov 18, 2026 | |
| $13.77 Nov 18, 2026 | $5.24B | 92 5-pillar Nov 18, 2026 | |
| $31.61 Nov 19, 2026 | $4.74B | 85 5-pillar Nov 18, 2026 | |
| $163.96 Nov 18, 2026 | $11.6B | 83 5-pillar Nov 18, 2026 | |
| $29.94 Nov 19, 2026 | $2.34B | 82 5-pillar Nov 18, 2026 | |
| $201.60 Nov 18, 2026 | $3.16B | 76 5-pillar Nov 18, 2026 | |
| $10.70 Nov 19, 2026 | $2.34B | 75 5-pillar Nov 18, 2026 | |
| $176.59 Nov 19, 2026 | $10.3B | 74 5-pillar Nov 18, 2026 | |
| $61.43 Nov 18, 2026 | $11.9B | 58 5-pillar Nov 18, 2026 | |
| $16.26 Nov 19, 2026 | $4.57B | 38 5-pillar Nov 18, 2026 | |
| $26.69 Nov 19, 2026 | $3.49B | 35 5-pillar Nov 18, 2026 | |
| Hims & Hers Health (HIMS) — this page | $16.02 | $3.76B | 31 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $24.00 – $40.00
- Consensus target
- $31.00
- Median target
- $32.00
Consensus record · Captured .
Measured against a quoted price of $16.02 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 11, 2026
- Transactions
- 98
- Identified insiders
- 17
- Purchases
- 0
- Sales
- 16
- Other transactions
- 82
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held HIMS in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported HIMS in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Hims & Hers Health (HIMS)?
Hims & Hers Health Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does Hims make money from sexual health and hair care products?
These are over-the-counter categories sold directly through the platform alongside prescription consultations, expanding the customer's lifetime value by creating additional purchasing occasions. The company's portfolio combines recurring prescription revenue with non-recurring product sales.
What does the recent insider selling tell us?
Over the most recent period, insiders have executed net sales with no corresponding purchases, with the heaviest activity occurring most recently. This pattern typically reflects either tax-motivated rebalancing or loss of conviction about near-term stock recovery. Insiders who are confident in the business trajectory typically maintain consistent ownership levels.
Why did profitability evaporate in the latest quarters even as revenue accelerated?
Operating expenses remain partially fixed, and the most recent periods saw elevated spending on research and development alongside continued deployment of sales and marketing infrastructure. The deterioration suggests the company prioritized market position over near-term earnings, betting that scale will eventually drive margin improvement.
Is the balance sheet stable enough to support current revenue trajectory?
Liquid assets cover less than would be required for an extended revenue decline, while total debt exceeds liquid resources significantly, meaning the company relies on sustained cash generation from operations. A sharp downturn in revenue growth would force the company to issue equity or cut spending, both dilutive to current shareholders.
What is the HIMS stock price today?
The last price recorded for Hims & Hers Health, Inc. (HIMS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the HIMS price target?
The analyst consensus price target for Hims & Hers Health, Inc. (HIMS), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 21 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com